Pharmaceuticals, Biotechnology and Life Sciences
Moderna, Inc. (NASDAQ:MRNA) has announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna COVID-19 vaccine (mRNA-1273) in children 6 months to under 2 years and 2 years to under 6 years of age.
ONK Therapeutics has appointed Allan Reine as independent Non-Executive Director to its Board.
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
– VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden…
Bristol Myers Squibb has announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session, taking place in Washington, DC, and virtually, from April 2-4, 2022.
Moderna has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, has announced the first close of its third fund at EUR 49 million.
Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, has announced the opening of a sales office in New York (NY) and a production facility in Gaithersburg (DE) to accelerate the company’s growth.
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for AstraZeneca’s Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).